TaiMed Biologics is ready to showcase its cutting-edge HIV therapies at BioAsia 2024, the largest Bio exhibition in Asia. As a leader in HIV treatment, TaiMed will highlight three key assets in our HIV portfolio: Trogarzo, a commercialized mAb therapy; TMB-365/TMB-380, a clinical-stage long-acting dual mAb combination; and an advanced Antibody-Drug Conjugate (ADC) platform.
Trogarzo has revolutionized HIV treatment, providing patients with a novel therapeutic option that offers enhanced efficacy and safety profiles. Building on this success, our long-acting dual mAb combination TMB-365/TMB-380, currently in Phase 2 trials, aims to improve patient adherence and outcomes through its extended dosing interval.
We are also excited to present our latest innovation—a pioneering ADC project. This cutting-edge therapy platform represents the next frontier in HIV treatment, combining the precision of monoclonal antibodies with the potent efficacy of drug conjugates to target HIV-infected cells more effectively.
Visit us at Booth# M104 to learn more about our innovative therapies and how we are transforming the landscape of HIV treatment. Our experts will be available for discussions and to answer any questions you may have about our groundbreaking work.
https://expo.bioasiataiwan.com/visitorExNewsDetail.asp?id=15573